Kumar Raja: Yeah. I was wondering what you’re saying in terms of a screen failure rate there?
Kelly McKee: Screen failure, yeah. So that’s really a hard question to answer because the patients that are offered to us by our site investigators are those that are sort of at the end of their other therapeutic options. And patients tend to be pre-identified at some point well in advance of the time that they’re really ready to enroll in our trial. And whether they start — whether they show a response to a current therapeutic regimen that they’re on or whether they find themselves in such dire straits because of their underlying disease that they don’t qualified because of abnormal blood chemistries or cardiac failure or whatever. It’s kind of all over the place. And so we don’t really see — patients aren’t screened unless they sort of get to the point where they’re in a position where the investigator thinks there’s a reasonable chance that they could enroll in our trial.
Now once they get to that point, I would guess that our screen failure rate is probably somewhere in the neighborhood of 25% to 50%.
Kumar Raja: Okay. That’s great.
Operator: Thank you. And our next question comes from Jeffrey Kraws with Crystal Research. Please state your question.
Jeffrey Kraws: Thank you very much. Many of my questions were already asked. But the questions remain, you just addressed ASCO, but you expected it presenting any scientific papers or scientific presentations or data set presentations at any of the three scientific conferences that you’re attending?
Kelly McKee: For Gedeptin or for
Jeffrey Kraws: For anything.
Kelly McKee: Yeah.
Jeffrey Kraws: We’re just not at ASCO. We got there too, yes.
Kelly McKee: Right. Yes. There’s going to be data presented at the World Vaccine Congress in early April. There’s going to be data on CMO4S1. There’s going to be data presented at the Vaccine Summit in Boston, I guess, that’s early June or maybe late May. On CMO4S1 and then there’s a Flow Cytometry Conference, sorry, Cytometry Conference in May where some data that’s sort of the lab with more technical lab stuff associated with our trial is going to be presented as well.
Jeffrey Kraws: Fantastic. I know you’ve been working very hard to move that along. So that’s great news. The second question is, with regard to the manufacturing and having that is one of your goals. If one was to look at your manufacturing validation that you want to have and just say you hope to have it by a certain date, what would you say the percentage of working towards that is complete now? I’m not asking you for what the specific guide is, you say, you’re 50% there, 60% there, 80% there, just roughly.
Kelly McKee: Mark, John, that’s yours.
Mark Newman: What so — we have different viral vector vaccines, right? So we’re in the Ebola field. We’ve got O4S1, which is the other COVID first step towards the universal COVID vaccine. And you match each of these, well, we are at least evaluating each of these with different cell lines for expression systems, and that’s a stepwise process. So the first thing you want to know is that a particular virus will grow in a particular cell line and sometimes they don’t. Sometimes the answer causes a toxicity. And these cell lines could be duck origin or chicken origin. They’re all tumor cell type of lines, but with slightly different genetic variations based on the bird you get it from. So you march through the series of events and say, which cell line supports which virus.
